uniQure (NASDAQ:QURE) Stock Price Down 5.8% – Should You Sell?

uniQure N.V. (NASDAQ:QURE) dropped 5.8% on Friday . The company traded as low as $23.13 and last traded at $22.99. Approximately 91,268 shares traded hands during trading, a decline of 95% from the average daily volume of 1,889,116 shares. The stock had previously closed at $24.40.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Technical strength signal — coverage notes uniQure met an 80-plus relative strength benchmark, which can attract momentum investors and offset some selling pressure. Read More.
• Neutral Sentiment: Near-term catalyst — uniQure is scheduled to release earnings this week; results and guidance could swing sentiment and either aggravate or alleviate current selling related to the lawsuits. Read More.
• Negative Sentiment: Class-action filing by Kessler Topaz alleges securities fraud covering the Sept. 24–Oct. 31, 2025 period and sets an April 13, 2026 lead‑plaintiff deadline — this is a direct legal headline likely to weigh on the stock. Read More.
• Negative Sentiment: Multiple law firms (Schall, Faruqi & Faruqi, Pomerantz, Rosen, DJS, Bronstein Gewirtz & Grossman, Bernstein Liebhard, Portnoy, ClaimsFiler and others) have issued investor alerts and filings reminding shareholders of deadlines — the volume of notices magnifies perceived risk and creates sustained news flow and potential selling pressure. Read More.
• Negative Sentiment: Investor outreach emphasizes recoveries for specific loss thresholds and encourages lead‑plaintiff motions — if a strong lead plaintiff emerges, the case could proceed aggressively, increasing potential cost and uncertainty for the company. Read More.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. The Goldman Sachs Group reduced their price objective on uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a research note on Wednesday, January 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Stifel Nicolaus lowered their price objective on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Finally, Wall Street Zen cut shares of uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Ten equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, uniQure has a consensus rating of “Moderate Buy” and an average target price of $58.33.

uniQure Stock Performance

The business’s fifty day simple moving average is $23.60 and its 200-day simple moving average is $29.43. The firm has a market cap of $1.46 billion, a P/E ratio of -5.34 and a beta of 0.66. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23.

Insider Transactions at uniQure

In other news, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the transaction, the director directly owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares of the company’s stock, valued at $796,260.04. The trade was a 44.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.79% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC lifted its position in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares during the period. Aberdeen Group plc raised its stake in uniQure by 25.1% in the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares in the last quarter. State Street Corp raised its stake in uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after buying an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after buying an additional 1,785,275 shares during the period. Finally, Jefferies Financial Group Inc. bought a new stake in uniQure during the 2nd quarter valued at approximately $29,217,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.